HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome

Background Colposcopy is recommended once human papillomavirus (HPV)16/18 infection detected. However, not all HPV16/18-positive women will necessarily develop cervical lesions. Therefore, this study aimed to investigate the application of quantitative HPV16 E7 oncoprotein detection as a cancer screening method for more efficient while minimizing unnecessary colposcopy. Methods (HPV16) was quantitatively detected in exfoliated cells HPV16-positive women. The levels different degrees lesions were compared, and optimal cut-off value identifying HSIL+ determined by receiver operating characteristic (ROC) curve analysis. With pathological diagnosis gold standard, sensitivity (SEN), specificity (SPE), positive predictive (PPV), negative (NPV), Kappa calculated verify diagnostic method. Women diagnosed with low-grade squamous intraepithelial (LSIL) normal followed up 5 years evaluate protein disease progression/persistent infection. Results expression level positively correlated degree lesion (r = 0.589, P < 0.01). area under ROC (AUC) 0.817 (confidence interval: 0.729–0.904). 8.68 ng/ml. SEN, SPE, PPV, NPV, values identification 87.1%,70.0%, 87.1%, 70.0%, 0.571, respectively, which higher than those ThinPrep cytology test (TCT). NPV predicting 93.75%, 91.30%, 88.24%, 95.45%, respectively. Conclusion HPV 16 can only accurately screen but also achieve colposcopy referral. Additionally, predict progression persistent